Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Ministry of Health, Labour and Welfare to evaluate zolbetuximab as treatment option for patients with advanced gastric and gastroesophageal cancers
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Subscribe To Our Newsletter & Stay Updated
